Some things will always remain unfettered. Like sunshine and air, like suffering and joy, like sharing and caring. Some things will never recognize the confines of space and time. Like human endeavour and enterprise, like the desire to touch life. At Morepen, we are taking our expertise and experience in Wellness to new countries and new people with an increasing focus on global exports. And in doing so, our spirit of caring is crossing boundaries.
Net Profit After Tax for Q2’FY2020-21 has grown sharply by 566 percent at Rs. 27.17 crore while Net Profit Before Tax jumped up by 198 percent on account of better margin realization during the quart... (more)
Morepen Laboratories Ltd. has reported a 16.43 per cent rise in its Net Profit (Consolidated) at Rs. 33.58 crore. Net Consolidated Revenue during the year rose by 11.7 per cent at Rs. 862.55 crore. The company’s net profit was Rs. 28.84 crore on a net revenue of Rs. 772.21 crore in the p... (more)
Morepen Laboratories Ltd. has received the prestigious ISO-13485 certification from BSI (British Standards Institution, U.K.) for its State-of-the-art medical devices manufacturing facility at Baddi (Himachal Pradesh). The certification has been awarded for the manufacturing, distribution and after... (more)
Morepen Laboratories Ltd. is all set to be a frontrunner in India’s fight against Novel Coronavirus Disease (popularly referred to as COVID-19). The company has launched a wide range of essential products being required to combat the growing menace of COVID-19 and to prevent further spread of... (more)
Highlights of Q3' FY 2019-20 (Consolidated)
The Net Profit after Tax during the period stood at Rs. 10.81 crore, up by 21.3 per cent from Rs. 8.91 crore net profit registered in the corresponding period of FY’2018-19.
Net Sales Revenue recorded a growth ... (more)
Highlights of First Half (H1) FY 2019-20 (Standalone)
Net Sales Revenue recorded a growth of 24.2 per cent at Rs. 383.30 crore in H1 FY 2019-20 as compared to Rs. 308.56 crore in the corresponding first half of the previous fiscal.
EBIDTA was up by 31.8 per ce... (more)
Three new Drugs viz., Rivaroxaban (Cardiac Segment), Vildagliptin (Diabetes segment) and UDCA (for Liver ailments) added to API portfolio.
Commercial launch of all the three drugs announced by the company, supplies to commence soon.
Global market size of Rivaroxaban is $7.1... (more)
Net Sales Revenue recorded a pure organic growth of 25.4 per cent at Rs. 186.70 crore in Q1’FY 2019-20 as compared to Rs. 148.83 crore in the corresponding quarter of the previous fiscal
